Chuan Tian

Also affiliated with Guangdong Medical College, University of Canterbury, Nanjing General Hospital of Nanjing Military Command, Guizhou Cancer Hospital, Affiliated Hospital of Guizhou Medical University, Nanjing Medical University, Nanjing University, Incyte (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies”.

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Annals of Oncology(2022)10.1016/j.annonc.2022.02.001

N/A

4.9DataRank · unranked

200 citations

Nicholas Iannotti, Martin Gutierrez, David C. Smith, Luis Féliz, Christine Lihou +5 more